Idiopathic detrusor sphincter dyssynergia in neurologically normal patients with voiding abnormalities.
Jørgensen TM, Djurhuus JC, Schrøder HD.
Eur Urol. 1982;8(2):107-10. doi: 10.1159/000473490.
Idiopathic detrusor-urethral dyssynergia in dogs: a retrospective analysis of 22 cases.
Díaz Espiñeira MM, Viehoff FW, Nickel RF.
J Small Anim Pract. 1998 Jun;39(6):264-70. doi: 10.1111/j.1748-5827.1998.tb03648.x.
Chinese botulinum toxin A for the treatment of lower urinary tract dysfunction: It works just as well.
Zhang F, Liu Q, Liao L, Li X, Zhang X.
Bladder (San Franc). 2022 Sep 14;9(1):e47. doi: 10.14440/bladder.2022.847. eCollection 2022.
[THE USE OF BOTULINUM TOXIN IN UROLOGY].
Anis O, Kitrey ND.
Harefuah. 2021 Sep;160(9):615-618.
Botulinum toxin as a new therapy option for voiding disorders: current state of the art.
Leippold T, Reitz A, Schurch B.
Eur Urol. 2003 Aug;44(2):165-74. doi: 10.1016/s0302-2838(03)00250-1.
Botulinun A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction.
Kuo HC.
Tzu Chi Med J. 2016 Jul-Sep;28(3):89-93. doi: 10.1016/j.tcmj.2016.07.001. Epub 2016 Aug 28.
Botulinum toxin in urology: evaluation using an evidence-based medicine approach.
Smith CP, Somogyi GT, Boone TB.
Nat Clin Pract Urol. 2004 Nov;1(1):31-7. doi: 10.1038/ncpuro0034.
Current and potential urological applications of botulinum toxin A.
Jiang YH, Liao CH, Kuo HC.
Nat Rev Urol. 2015 Sep;12(9):519-33. doi: 10.1038/nrurol.2015.193. Epub 2015 Aug 11.
Botulinum toxin for conditions of the female pelvis.
El-Khawand D, Wehbe S, Whitmore K.
Int Urogynecol J. 2013 Jul;24(7):1073-81. doi: 10.1007/s00192-012-2035-1. Epub 2013 Jan 24.
Urologic applications of botulinum toxin therapy for voiding dysfunction.
Rackley R, Abdelmalak J.
Curr Urol Rep. 2004 Oct;5(5):381-8. doi: 10.1007/s11934-004-0088-5.
